Building on the very promising data from the early-stage trial, Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has launched the phase II evaluation of.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has successfully raised €7.1 million in a share offering, securing new investment to continue the cancer.
In an exclusive interview with Thomas Warner from Proactive, Dr Markku Jalkanen, chief executive of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF),.